



Marina Rodríguez-Marin ([marina.rmarin@quironsalud.es](mailto:marina.rmarin@quironsalud.es)). Mayra Gabriela Urtecho. Miguel Mallol. Servicio de Farmacia Hospital Universitario Ruber Juan Bravo, Madrid.

## Background and Importance

Pembrolizumab is a monoclonal antibody directed against the PD-1 surface protein. The Therapeutic Positioning Report on pembrolizumab indicates that efficacy and safety are comparable and do not present clinically significant variations

## Aim and Objectives

The objective of this study is to analyze, the effectiveness of weight-based dosing of the active ingredient, and the potential opportunity cost compared to fixed dosing.

## Material and Methods


### The variables studied were:

- Sex
- Age
- Weight
- Diagnoses
- Administered cycles
- Cost of treatment

The published articles were reviewed to assess the treatment's effectiveness and safety.



## Results



## Conclusion and Relevance

Weight-based dosing of pembrolizumab generates a significant opportunity cost without impacting efficacy or safety

